ChiCTR2000030152 版本V1.1 版本创建时间2020/03/28 11:00:59 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000030152 

最近更新日期:

Date of Last Refreshed on:

2020-03-28 11:00:50 

注册时间:

Date of Registration:

2020-02-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

徐龙医师:该研究尚未获得伦理委员会批准。请于批准后再开始纳入参试者,并与我们联系上传批件。 经自然腔道(胃壁)内镜下保胆取石术的前瞻性非随机对照临床试验

Public title:

A prospective non-randomized controlled clinical trial of transgastric gallbladder-preserving cholecystolithotomy via pure natural orifice transluminal endoscopic surgery

注册题目简写:

NOTES

English Acronym:

NOTES

研究课题的正式科学名称:

经自然腔道(胃壁)内镜下保胆取石术的前瞻性非随机对照临床试验

Scientific title:

A prospective non-randomized controlled clinical trial of transgastric gallbladder-preserving cholecystolithotomy via pure natural orifice transluminal endoscopic surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐龙 

研究负责人:

杨公利 

Applicant:

Xu Long 

Study leader:

Yang Gongli 

申请注册联系人电话:

Applicant telephone:

+86 18971519478

研究负责人电话:

Study leader's telephone:

+86 13886827389

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

dlxulong@aliyun.com

研究负责人电子邮件:

Study leader's E-mail:

372073843@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

深圳市南山区学苑大道1098号

研究负责人通讯地址:

深圳市南山区学苑大道1098号

Applicant address:

1098 Xueyuan Avenue, Nanshan District, Shenzhen, Guangdong, China

Study leader's address:

1098 Xueyuan Avenue, Nanshan District, Shenzhen, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

深圳大学总医院

Applicant's institution:

Shenzhen University General Hospital

研究负责人所在单位:

深圳大学总医院

Affiliation of the Leader:

Shenzhen University General Hospital

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

深圳大学总医院

Primary sponsor:

Shenzhen University General Hospital

研究实施负责(组长)单位地址:

深圳市南山区学苑大道1098号

Primary sponsor's address:

1098 Xueyuan Avenue, Nanshan District, Shenzhen, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳大学总医院

具体地址:

深圳市南山区学苑大道1098号

Institution
hospital:

Shenzhen University General Hospital

Address:

1098 Xueyuan Avenue, Nanshan District, Shenzhen

经费或物资来源:

Source(s) of funding:

none

Target disease:

gallbladder stone

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

单臂 

Study design:

Single arm 

研究目的:

了解经自然腔道内镜下保胆取石术的安全性、并发症,术后胆囊功能改善情况,术后胆囊结石复发情况及其可能的高危因素。  

Objectives of Study:

To evaluate the safety of transgastric gallbladder-preserving cholecystolithotomy via pure natural orifice transluminal endoscopic surgery, to know changes of gallbladder function , the recurrence rate of gallstone and the possible high risk factors after NOTES.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.胆囊大小基本正常,胆囊壁厚≦5mm;
2.胆囊功能良好;
3.胆囊管无结石梗阻;
4.胆囊结石少,不要超过10个;
5.近期无急性发作;
6.病人有明确的保胆要求,并且完全理解结石复发的可能性;
7. 年龄18-65周岁,无严重心肺肝肾功能不全,无抗凝药服用史

Inclusion criteria

1. The size of gallbladder is basically normal, the thickness of gallbladderwall is not more than 5 mm;
2. the function of gallbladder is normal;
3. No stone obstruction of cystic duct;
4. No more than 10 gallstones;
5. No acute attack of cholecystitis in the near future;
6. The patient has a clear requirement for gallbladder preservation and fully understands the possibility of stone recurrence;
7. Aged 18-65 years old, no severe cardiopulmonary insufficiency and hepatorenal insufficiency, no history of taking anticoagulant drugs.

排除标准:

1.胆囊炎症明显;
2.胆囊充满型结石;
3.胆囊分隔;
4.胆囊萎缩;
5.伴发胆管结石或急性胰腺炎;
6. 可疑胆囊恶性肿瘤;
7.胃大部切除术后;
8.严重糖尿病病人;
9.哺乳或妊娠患者

Exclusion criteria:

1. Acute cholecystitis;
2. Gallbladder full of stones;
3. Gallbladder separation;
4. Atrophy of gallbladder;
5. Cholelithiasis or acute pancreatitis;
6. Suspected malignant tumor of gallbladder;
7. History of subtotal gastrectomy;
8. Serious diabetes mellitus;
9. Lactation or pregnancy.

研究实施时间:

Study execute time:

From 2020-03-01 00:00:00 To 2025-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-03-01 00:00:00 To 2025-04-01 00:00:00  

干预措施:

Interventions:

组别:

病例组

样本量:

100

Group:

case group

Sample size:

干预措施:

经自然腔道内镜手术

干预措施代码:

Intervention:

Transgastric gallbladder-preserving cholecystolithotomy via pure natural orifice transluminal endoscopic surgery

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China 

Province:

Guangdong province 

City:

 

单位(医院):

深圳大学总医院 

单位级别:

三级 

Institution
hospital:

Shenzhen University General Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

胆囊结石复发率

指标类型:

主要指标

Outcome:

Recurrence rate of gallstone

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胆囊收缩功能

指标类型:

主要指标

Outcome:

Contraction function of gallbladder

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胆囊壁厚度

指标类型:

次要指标

Outcome:

Gallbladder wall thickness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

急性胆囊炎发作次数

指标类型:

次要指标

Outcome:

Incidence of of acute cholecystitis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胆总管结石发生率

指标类型:

次要指标

Outcome:

Incidence of choledocholithiasis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

Length of hospitalization

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院花费

指标类型:

次要指标

Outcome:

Cost in hospitalization

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中转外科手术率

指标类型:

次要指标

Outcome:

Transfer rate for surgical operation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腹腔感染率

指标类型:

次要指标

Outcome:

Abdominal infection rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

输血率

指标类型:

次要指标

Outcome:

Transfusion rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

死亡率

指标类型:

主要指标

Outcome:

Mortality

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症发生率

指标类型:

主要指标

Outcome:

Incidence of complications

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胆囊胆汁漏发生率

指标类型:

次要指标

Outcome:

Incidence of gallbladder bile leakage

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃壁穿孔闭合率

指标类型:

次要指标

Outcome:

Closure rate of gastric perforation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术时间

指标类型:

次要指标

Outcome:

Operative time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

胆囊内胆汁

组织:

Sample Name:

Bile in gallbladder

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

胆囊腔内活检组织

组织:

Sample Name:

Intraluminal biopsy of gallbladder

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

未使用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not used

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Not stated

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not stated

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Not stated

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Not stated

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-02-24 10:14:55